赫赛汀联合阿霉素脂质体治疗HER-2阳性乳腺癌的肿瘤负荷及毒副反应评估

Assessment of the tumor load as well as toxic and side effects after herceptin combined with doxorubicin liposome treatment of HER-2 positive breast cancer

目的：研究赫赛汀联合阿霉素脂质体治疗对人表皮生长因子受体-2（HER-2）阳性乳腺癌肿瘤负荷及毒副反应的影响。方法：选择2014年7月-2015年12月在本院接受化疗的138例HER-2阳性乳腺癌患者作为研究对象,随机分为两组（n=69）,脂质体组接受赫赛汀联合阿霉素脂质体治疗、对照组接受赫赛汀联合阿霉素治疗。治疗后8周时,测定血清中肿瘤标志物、活性分子、心肌损伤标志物的含量以及外周血单个核细胞中免疫标志分子的表达量。结果：治疗后8周时,脂质体组患者血清中CEA、CA199、CA153、CA125、VEGF、nectin-4、TK-1、PF-4、TSGF、CK、CK-MB、cTnⅠ、cTnT的含量显著低于对照组,外周血单个核细胞表面CD3、CD4、CD8、CD16、CD19、CD25的荧光强度显著高于对照组,差异有统计学意义（P〈0.05）。结论：赫赛汀联合阿霉素脂质体治疗HER-2阳性乳腺癌能够更为有效地降低肿瘤负荷且心脏及免疫系统的毒副作用较轻。

Objective：To study the effect of herceptin combined with doxorubicin liposome treatment on tumor load as well as toxic and side effects of HER-2positive breast cancer.Methods：A total of 138 patients with HER-2positive breast cancer who received chemotherapy in our hospital between July 2014 and December 2015 were selected as the research subjects and randomly divided into two groups（n=69）,liposome group received herceptin combined with doxorubicin liposome treatment and control group received herceptin combined with doxorubicin treatment.After 8weeks of treatment,the content of tumor markers,active molecules and myocardial injury markers in serum as well as the expression levels of immune marker molecules in peripheral blood mononuclear cells were detected.Results：After 8weeks of treatment,CEA,CA199,CA153,CA125,VEGF,nectin-4,TK-1,PF-4,TSGF,CK,CK-MB,cTnI and cTnT content in serum of liposome group were significantly lower than those of control group,and the fluorescence intensity of CD3,CD4,CD8,CD16,CD19 and CD25on peripheral blood mononuclear cell surface were significantly higher than those of control group.Conclusion：Herceptin combined with doxorubicin liposome treatment of HER-2positive breast cancer can more effectively reduce the tumor load and cause less toxic and side effects on the heart and the immune system.